TFPI2 makes glioblastoma more vulnerable to NK cells

What is it about?

Glioblastoma is one of the most aggressive types of brain cancer. Current treatments, including surgery, radiotherapy, and chemotherapy, can slow the disease but usually cannot prevent recurrence. New immune-based treatments are therefore urgently needed. Natural killer cells, or NK cells, are immune cells that can recognize and kill cancer cells without needing prior training. However, glioblastoma often creates an environment that weakens immune attack, making it difficult for NK cells to work effectively. In this study, we asked how glioblastoma cells respond when they are attacked by NK cells, and whether this response can influence the success of immune killing. We found that NK cell attack causes glioblastoma cells to increase the level of a protein called TFPI2. Rather than helping the tumor escape, TFPI2 makes the tumor cells more vulnerable to NK cells. TFPI2 works in two important ways. First, it helps maintain the expression of ICAM1, a molecule that allows NK cells and tumor cells to attach to each other more strongly. This close contact is important because NK cells need to form a stable interaction with cancer cells before they can kill them efficiently. Second, TFPI2 reduces the expression of SIGLEC15, an immune checkpoint molecule that can suppress NK cell activity. In other words, TFPI2 both helps NK cells stick to glioblastoma cells and removes part of the tumor’s inhibitory signal. We also showed that when TFPI2 is reduced, glioblastoma cells grow faster and become less sensitive to NK cell killing. In mouse models, tumors with lower TFPI2 grew more aggressively and responded poorly to NK cell therapy. Together, our findings suggest that TFPI2 is an important mediator of the interaction between NK cells and glioblastoma cells. Enhancing or preserving TFPI2 activity may be a useful strategy to improve NK cell-based immunotherapy for glioblastoma.

Featured Image

Photo by Marek Piwnicki on Unsplash

Photo by Marek Piwnicki on Unsplash

Why is it important?

One distinctive aspect of this work is that it highlights a potentially beneficial tumor-cell response during immune attack. Tumor responses to immune pressure are often discussed in the context of immune escape. In this study, we found that NK cell treatment can also induce TFPI2 expression in glioblastoma cells, and this response appears to make tumor cells more susceptible to NK cell-mediated killing. Our findings suggest that TFPI2 may connect several important processes in antitumor immunity. Mechanistically, TFPI2 supports the TFPI2–LGALS1–ICAM1 axis, which may help strengthen the physical interaction between NK cells and glioblastoma cells. At the same time, TFPI2 suppresses SIGLEC15, an inhibitory immune checkpoint molecule that can reduce NK cell activity. In this way, TFPI2 may help coordinate both immune-cell adhesion and checkpoint control. This work is timely because glioblastoma remains difficult to treat, and NK cell-based immunotherapy is being actively explored as a potential therapeutic strategy for solid tumors. However, the effectiveness of NK cell therapy can vary greatly depending on the tumor microenvironment and tumor-intrinsic features. Our results suggest that the ability of glioblastoma cells to induce TFPI2 under inflammatory or immune-stimulated conditions may be one factor influencing their response to NK cell attack. Importantly, our discussion also emphasizes that TFPI2 function is context dependent. Therefore, TFPI2 is unlikely to be a universal therapeutic target for all glioblastomas. Instead, it may serve as a candidate biomarker or therapeutic entry point for a subset of glioblastomas that retain inflammatory responsiveness. In the future, restoring TFPI2 activity or mimicking its downstream effects on ICAM1 and SIGLEC15 could help improve NK cell-based or combination immunotherapy strategies.

Perspectives